SPONTANEOUS TUMOR LYSIS SYNDROME IN A CASE OF MULTIPLE MYELOMA
نویسندگان
چکیده
منابع مشابه
Spontaneous Tumour Lysis Syndrome in a Multiple Myeloma
The tumor lysis syndrome (TLS) is a collection of metabolic abnormalities that occur in consequence of the release of intracellular contents following lysis of tumor cells. TLS occurs spontaneously or after chemotherapy. Spontaneous TLS is uncommon occurrence in multiple myeloma (MM). We define a case of a 70-year-old woman patient who was found to have MM with spontaneous TLS, following a comp...
متن کاملTumor lysis syndrome in a multiple myeloma treated with thalidomide.
A 60-year-old male with progressive high burden non-secretory multiple myeloma (NSMM) presented with tumor lysis syndrome (TLS) after starting thalidomide. He was diagnosed in 1998 with NSMM stage IIIA according to Durie and Salmon’s classification. Initial treatment consisted of six cycles of vincristine, doxorubicin and dexamethasone (VAD), and double high doses of melphalan supported by auto...
متن کاملSpontaneous Tumor Lysis Syndrome
Tumor lysis syndrome (TLS) is a known complication of malignancy and its treatment. The incidence varies on malignancy type, but is most common with hematologic neoplasms during cytotoxic treatment. Spontaneous TLS is thought to be rare. This case study is of a 62-year-old female admitted with multisystem organ failure, with subsequent diagnosis of aggressive B cell lymphoma. On admission, labo...
متن کاملA Case of Spontaneous Tumor Lysis Syndrome in Malignant Melanoma
A 62-year-old man with a complaint of back pain lasting 2 months was admitted. He also presented a huge abdominal tumor. Diagnostic imaging showed metastatic tumors in the liver, lumbar vertebrae and bilateral lung. An ultrasound-guided needle biopsy revealed a lung tumor containing melanic tissue. Subsequently, there was an evident elevation in uric acid, phosphoric acid, potassium and lactate...
متن کاملBortezomib-induced tumor lysis syndrome in multiple myeloma.
Tumor lysis syndrome (TLS) is exceedingly rare in multiple myeloma because of the relatively slow proliferation and response of the malignant cells. Bortezomib is a novel agent that inhibits proteasome and has shown activity against multiple myeloma. We report 8 episodes of TLS seen in 7 patients with bortezomib therapy, with or without dexamethasone, among 496 patients treated on 3 phase II mu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Australasian Medical Journal
سال: 2013
ISSN: 1836-1935
DOI: 10.21767/amj.2013.1592